CIK 0001410098 · Non-accelerated filer
CorMedix Inc.
Sign in to watch- Ticker
- CRMD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 908-517-9500
- Business address
- 389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise | +25,000 | $3.47 | $87K | 185,424 |
| 2024-11-14 | Hurlburt Elizabeth EVP | Sale | −140,027 | $11.18 | $1.6M | 45,397 |
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise · Stock Option (Right to Buy Common Stock) | −3 | 53,997 | ||
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise · Stock Option (Right to Buy Common Stock) | −8,169 | 12,711 | ||
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise · Stock Option (Right to Buy Common Stock) | −9,888 | 27,612 | ||
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise · Stock Option (Right to Buy Common Stock) | −34,467 | 3,033 | ||
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise · Stock Option (Right to Buy Common Stock) | −62,500 | 62,500 | ||
| 2024-11-14 | Hurlburt Elizabeth EVP | Option exercise · Stock Option (Right to Buy Common Stock) | −25,000 | 75,000 | ||
| 2024-10-31 | Mistry Erin EVP, Chief Commercial Officer | Purchase | +1,500 | $9.99 | $15K | 52,011 |
| 2024-05-10 | Todisco Joseph Chief Executive Officer | Shares withheld for taxes | −26,982 | $5.17 | $139K | 325,857 |
| 2024-03-13 | Todisco Joseph Chief Executive Officer | Purchase | +13,561 | $3.74 | $51K | 352,839 |
| 2024-03-05 | Lefkowitz Steven W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2024-03-05 | Stewart Robert A Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2024-03-05 | Kaplan Myron Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2024-03-05 | Dillione Janet Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2024-03-05 | DUNTON ALAN W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2024-03-05 | Duncan Gregory Scott Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2024-01-12 | Masson-Hurlburt Elizabeth EVP, Head of Clinical Ops. | Grant or award | +50,000 | 58,000 | ||
| 2024-01-12 | Masson-Hurlburt Elizabeth EVP, Head of Clinical Ops. | Shares withheld for taxes | −4,603 | $3.47 | $16K | 53,397 |
| 2024-01-12 | Masson-Hurlburt Elizabeth EVP, Head of Clinical Ops. | Grant or award · Stock Option (Right to Buy Common Stock) | +100,000 | 100,000 |
Page 7 of 9 · 176 trades